Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna will keep its COVID vaccine on the market at no cost to consumers, even after the federal government stops paying for it, the company announced Wednesday. "Everyone in the United States ...

If you're confident that its current trials will prove successful, then this is one to buy and sit on. One word of caution ...

In Moderna's first interim analysis, 95 people came down with COVID-19, 90 of whom received the placebo. Eleven people – all in the placebo group – developed "serious" cases of the disease.

US Centers for Disease Control and Prevention Director Dr. Rochelle Walensky signed off on a recommendation of Moderna’s Covid-19 vaccine for people ages 6 to 17, the agency announced Friday.

Moderna announced Monday that its COVID-19 vaccine booster increases antibody levels against the omicron variant within a month of getting the shot. In a lab study, the company gave 20 fully ...

Interim results of a Phase 2/3 trial showed Moderna’s Covid-19 vaccine was well-tolerated and generated a robust immune response in children ages 6 to 11, the company said Monday.

Carlo Allegri/Reuters [Read more on Moderna’s Covid-19 vaccine.] Pfizer has reported that its vaccine is 95 percent effective, so the estimates for the two vaccines are clearly in the same ballpark.

Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its COVID-19 ...